- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01037751
M. D. Anderson Symptom Inventory - Ovarian Cancer
M. D. Anderson Symptom Inventory - Ovarian Cancer: Development and Validation in Patients With Ovarian Cancer
Objectives:
The objective of this study is to delineate and measure the symptom burden experienced by patients with ovarian cancer.
The Primary Aim is to develop and validate an ovarian-cancer module of the M. D. Anderson Symptom Inventory (MDASI-Ovarian Cancer) to measure the severity of multiple symptoms and the impact of these symptoms on daily functioning in patients with ovarian cancers.
The Secondary Aims are:
To develop a detailed description of symptom severity and interference with daily activities experienced by patients with ovarian cancer; To assess the impact of symptom severity on standard functioning and quality of life (QOL) measures, including Eastern Cooperative Oncology Group Performance Status (ECOG PS), Functional Assessment of Cancer Therapy-Ovary (FACT-O), and a single-item QOL scale, in patients with ovarian cancer; To define the qualitative symptom burden of patients with ovarian cancer receiving various treatments.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PART 1:
Interview:
If you agree to take part in this study, you will be interviewed about what it is like to have ovarian cancer and any symptoms that you may have experienced. This will be a 1-on-1 interview with the study doctor or a member of the study staff. It will take place during 1 of your regularly scheduled, standard of care clinic visit and should take about 30 minutes to complete.
The interview will be digitally recorded. The electronic recording of the interview will be given a code number and stored on a password-protected computer at M. D. Anderson. No identifying information will be directly linked to your interview recording. Only the researcher in charge of the computer will have access to the code numbers and be able to link the interview recording to you.
Questionnaires:
After the interview, you will also complete a symptom questionnaire, a quality-of-life questionnaire, and a demographic questionnaire that asks questions about your age, race, and marital status. You will complete the questionnaires after the interview during the same clinic visit. It should take about 10 minutes to complete all 3 questionnaires.
You should contact the study doctor or study nurse right away if at any time you are experiencing severe, troublesome, or intolerable symptoms. You should also remember to rate them on the symptom questionnaire.
The questionnaires will also be given a code number and stored in a locked file cabinet at MD Anderson. No identifying information will be directly linked to your questionnaires. Only the researcher in charge of the study will have access to the code numbers and be able to link the questionnaires to you.
Length of Study:
After you have completed the interview and the questionnaires, your participation on this study will be over.
Additional Information:
Any information about your symptoms that is collected as part of this study is for research purposes only. All study materials, including the interview recording and questionnaires, will only be used for the purposes of this study and will be destroyed after the study results have been reported.
If you rate a symptom as severe on the symptom questionnaire, a study staff member will ask you if you have already told, or plan to tell your regular care doctor or nurse about the symptom. If you have not already told you regular care doctor or nurse, a study staff member will tell your regular care doctor or nurse about the symptom for you.
This is an investigational study.
Up to 15 participants will take part in this study. All will be enrolled at MD Anderson.
PART 2:
Questionnaires:
If you agree to take part in this study, you will complete the following:
- A symptom questionnaire, 2 quality-of-life questionnaires, and a demographic questionnaire that asks questions about your age, race, and marital status. It should take about 20 minutes to complete all 4 questionnaires.
- About 1 to 5 days after you complete the first set of questionnaires, you will be asked to complete a questionnaire either through phone interview with the study staff or through a mail-in survey . If you complete the questionnaire by mail-in survey, the study staff will give you a copy of the questionnaire and a stamped pre-addressed envelope. The questionnaire will take 5-10 minutes to complete.
You should contact the study doctor or study nurse right away if at any time you are experiencing severe, troublesome, or intolerable symptoms. You should also remember to rate them on the symptom questionnaire.
The questionnaires will be given a code number and stored in a locked file cabinet at M. D. Anderson. No identifying information will be directly linked to your questionnaires. Only the researcher in charge of the study will have access to the code numbers and be able to link the questionnaires to you.
Opinion Questionnaire:
If you are one of the first 20 patients enrolled in the study, you will be asked questions about your opinion of the symptom questionnaire. For example, you will be asked if the symptom questionnaire was easy to understand and complete, and if there were any other questions that should be included. The study staff will use your opinion to decide if changes should be made to the questionnaire or if important symptom questions are missing from the questionnaire. This questionnaire should take about 5 minutes to complete.
Length of Study:
After you have completed the questionnaires, your participation on this study will be over.
Additional Information :
Any information about your symptoms that is collected as part of this study is for research purposes only. The questionnaires will only be used for the purposes of this study and will be destroyed after the study results have been reported.
If you rate a symptom as severe on the symptom questionnaire, a study staff member will ask you if you have already told, or plan to tell your regular care doctor or nurse about the symptom. If you have not already told you regular care doctor or nurse, a study staff member will tell your regular care doctor or nurse about the symptom for you.
This is an investigational study.
Up to 128 participants will take part in this study. All will be enrolled at MD Anderson and Lyndon B. Johnson General Hospital.
Studietype
Inschrijving (Verwacht)
Contacten en locaties
Studie Locaties
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- University of Texas MD Anderson Cancer Center
-
Houston, Texas, Verenigde Staten, 77026
- Lyndon B. Johnson General Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Female patients 18 years of age or older.
- Able to speak and read English.
- Having a diagnosis of high grade invasive epithelial ovarian cancer, peritoneal cancer or fallopian tube cancer confirmed by pathological analysis.
- Being followed at M D Anderson Cancer Center and Lyndon B. Johnson General Hospital (LBJ Hospital).
- Has consented to participate.
- Has not received any current cancer treatment or prior chemotherapy in the last 30 days (phase 2 subset of 40 patients only)
Exclusion Criteria:
1) Having a medical condition or impaired performance status that would preclude participation in the study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Interview + Questionnaires
1-on-1 interview + Questionnaires, Part 1 of Study
|
1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
Andere namen:
|
|
Questionnaires
Questionnaires Only, Part 2 of Study
|
Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Validate ovarian-cancer module of MDASI-Ovarian Cancer to measure severity of multiple symptoms + impact of these symptoms on daily functioning in patients with ovarian cancers.
Tijdsspanne: Baseline to 2 years (Patient participation done after completing Interview and Surveys during single clinic visit)
|
Baseline to 2 years (Patient participation done after completing Interview and Surveys during single clinic visit)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Patient Rated Symptom Severity and Interference with Function (Survey Response)
Tijdsspanne: Baseline to 2 years
|
Baseline to 2 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Diane C. Bodurka, MD, BS, M.D. Anderson Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Urogenitale neoplasmata
- Neoplasmata per site
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Genitale neoplasmata, vrouwelijk
- Endocriene systeemziekten
- Ovariële ziekten
- Adnexale ziekten
- Gonadale aandoeningen
- Endocriene klierneoplasmata
- Ovariumneoplasmata
- Carcinoom, ovariumepitheel
Andere studie-ID-nummers
- 2009-0506
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Eierstokkanker
-
Sun Yat-sen UniversityNog niet aan het wervenCancer therapie-geïnduceerde trombocytopenie (CTIT)
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActief, niet wervendPancreas Adenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8 | Stadium 0 Pancreaskanker American Joint Committee on Cancer v8 | Stadium I alvleesklierkanker American Joint Committee on Cancer v8 | Stadium IV alvleesklierkanker American Joint Committee on Cancer...Verenigde Staten
-
Centre Hospitalier Universitaire, AmiensVoltooidEnt Cancer ScreeningFrankrijk
-
Hitit UniversityErol Olcok Corum Training and Research HospitalVoltooidHysterectomie (MeSH nr: E04.950.300.399) | Had een hysterectomie ondergaan | Had Not Been Diagnosed With Cancer | Na hysterectomieTurkije (Türkiye)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)VoltooidVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Xijing HospitalActief, niet wervendBorstkanker | Borstkanker (Triple Negative Breast Cancer (TNBC))China
-
Shanghai Henlius BiotechNog niet aan het wervenBorstkanker (Triple Negative Breast Cancer (TNBC))China
-
Shandong Cancer Hospital and InstituteWervingGeavanceerd ductaal adenocarcinoom van de alvleesklier | Cancer Anorexia-Cachexia SyndroomChina
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
Klinische onderzoeken op Interview
-
University of New MexicoVoltooidBeëindiging van de zwangerschapVerenigde Staten
-
Mayo ClinicNog niet aan het wervenSpontane dissectie van de kransslagaderVerenigde Staten
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, FranceVoltooidKanker | Ouderen | Etnografisch interview | Sociale representatie van ouder worden | Redenen van niet-deelname aan klinische onderzoeken | Kwalitatieve methodeFrankrijk
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... en andere medewerkersVoltooid
-
ARCIM Institute Academic Research in Complementary...Voltooid
-
University of ExeterUniversity of Nottingham; University of Bristol; National Institute for Health...VoltooidSuikerziekteVerenigd Koninkrijk
-
Sakarya UniversityActief, niet wervendVerpleegkundige opleiding | Geestelijke stoornis | Stigma van psychische aandoeningen | Impliciete associatietestKalkoen
-
Beth Israel Deaconess Medical CenterVoltooidDyspepsie | Maagzuur | Gastro-oesofageale refluxziekte (GERD)Verenigde Staten
-
J. Matthias WalzBrown UniversityVoltooid
-
Medical College of WisconsinNational Institute of Mental Health (NIMH)VoltooidHIV-preventie en beoordelingsreactiviteitZuid-Afrika